← Back to Search

Other

RTX-134 for Phenylketonuria

Q: Are there any unfilled spots still available in this trial?

<p>The information accessible on clinicaltrials.gov indicates that, despite being initially posted in January 2020 and edited as recently as October 2022, this trial is not presently recruiting participants. However, 19 other trials are actively enrolling right now.</p>

Q: What are the demonstrated safety profiles of RTX-134?

<p>RTX-134, of which there is limited evidence regarding safety and efficacy, received a score of 1 on our scale for determining its perceived risk level.</p>

Phase 1

Waitlist Available

Research Sponsored by Rubius Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 28 days after last detection of rtx-134

Awards & highlights

Study Summary

This trial will test a new drug, RTX-134, to see if it is safe and tolerated by adults with PKU.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 28 days after last detection of rtx-134

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 28 days after last detection of rtx-134

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 28 days after last detection of rtx-134 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To correlate dose with percent reduction in serum phenylalanine levels relative to baseline

To determine a preliminary dose to achieve serum phenylalanine levels < 360 µmol/L

To determine a preliminary dose to achieve serum phenylalanine levels < 600 µmol/L

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: RTX-134Experimental Treatment1 Intervention

Escalating doses of RTX-134 will be administered by intravenous infusion one time

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rubius TherapeuticsLead Sponsor

3 Previous Clinical Trials

85 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any unfilled spots still available in this trial?

"The information accessible on clinicaltrials.gov indicates that, despite being initially posted in January 2020 and edited as recently as October 2022, this trial is not presently recruiting participants. However, 19 other trials are actively enrolling right now."

Answered by AI

What are the demonstrated safety profiles of RTX-134?

"RTX-134, of which there is limited evidence regarding safety and efficacy, received a score of 1 on our scale for determining its perceived risk level."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

2020. "Safety and Tolerability of RTX-134 in Adults With Phenylketonuria". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04110496.